Real-world Perspectives on the Role of TYK2 Inhibitors in the Treatment of Psoriasis
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Real-world Perspectives on the Role of TYK2 Inhibitors in the
Treatment of Psoriasis
• Interim Outcomes Report (6 month)
• Enduring Availability: September 30, 2021 – September 30, 2022
• https://www.mycme.com/courses/real-world-perspectives-on-the-role-of-tyk2-inhibitors-in-
the-treatment-of-psoriasis-7860
• Pending release on Epocrates, estimated April 1, 2022 – September 30, 2022
• Sponsored by the Academy for Continued Healthcare Learning (ACHL)
• Primary Contact: Amanda Kaczerski, MS, CHCP (akaczerski@achlcme.org)
• Data as of: February 25, 2022
• Date Submitted: March 8, 2022
• Moore's Outcomes Levels: 1-4
Level Planned Level Reached
Level 4 Level 4
Medical Education
BMS Grant ID 67832115 Confidential 1
Real-world Perspectives on the Role of TYK2 Inhibitors in the Treatment Faculty
of Psoriasis (BMS Grant ID # 67832115) • April Armstrong, MD, MPH
• Neal Bhatia, MD
• Provided by the Academy • Total Cost of Activity: LEARNER PARTICIPATION • Mark Lebwohl, MD
for Continued Healthcare $97,375
Total Actual Unique Learners
Learning (ACHL) BMS Support: $97,375
• September 30, 2021 – Meeting Agenda
BMS Cost per Learner: TOTAL
MDs/DO NP/PA PharmD Other
September 30, 2022 $81.15 (est. 1200 Learners
• CME Link: participants) • TYK2 Inhibition: A Rational and Effective Approach to
https://www.mycme.com/cou 259 28% (73) 57% (148) 1% (3) 14% (35) Psoriasis
rses/real-world-perspectives- • Target Audience • Immunological pathways involved in the
on-the-role-of-tyk2-inhibitors- • Other HCPs include nurses, case managers, dietitian pathogenesis of psoriasis
in-the-treatment-of-psoriasis-
dermatologists,
7860 dermatology NPs & PAs,
and unknown (guest users) • The JAK/STAT pathway as a rational approach
Direct to Activity: primary care providers, Breakdown of Physician Learners • Unmet clinical needs and novel targets
https://www.achlcme.org/dig and other healthcare TOTAL
• Latest TYK2 inhibitor clinical evidence –make
ital/PSO210/index.html providers who treat Dermatolog GP/Internal primary focus of this section
Physician Other • Ongoing trials with TYK2 inhibitors in psoriasis
patients with psoriasis. ists Medicine
Learners
• Distinguishing TYK2 inhibitors from more
Credit Offered 72 29% (21) 32% (23) 39% (28) conventional JAK inhibitors
• 1.00 AMA PRA Category 1 Credit • Real World Perspectives on Incorporating Novel and
• Other HCPs include cardiologists, hospitalists, Emerging Therapeutics into an Optimal Treatment
orthopedics, immunologists, surgeons Approach
Learning Objectives US vs Ex-US Learners • Current treatment paradigms
• Evaluate emerging TYK2 inhibitors based on their US Ex-US • Patient selection criteria
mechanistic profiles, safety, efficacy and routes of • Moving toward personalized management
administration 98% (254) 2% (5) strategies
• Assess clinical implications of emerging evidence for in • Application of latest clinical evidence to
treatment paradigm
meeting unmet clinical needs for refractory psoriasis
patients • Limitations of guidelines
Post Activity Gains Up to 970 • Defining targets and timelines
• Model current and future treatment strategies for refractory
30% (n=216) patients • Mitigating risks
patients considerate of disease activity, treatment response,
Average increase in impacted • Shared decision-making approaches
and other patient-specific factors knowledge and weekly
competence
2
Faculty
April Armstrong, MD, MPH
Professor of Dermatology
Associate Dean for Clinical Research
Director of Clinical Research Support, Southern California Clinical and Translational Science Institute
Vice Chair | Director, Clinical Trials and Outcomes Research | Director, Psoriasis Program
Keck School of Medicine at USC
University of Southern California
Los Angeles, CA
Neal Bhatia, MD
Director of Clinical Dermatology
Therapeutics Clinical Research
San Diego, CA
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
Medical Education
BMS Grant ID 67832115 Confidential 3
Learner Demographics
Anticipated “Attendance” per portal submission vs actual
participants (an HCP who viewed the CME/CE front matter)
Anticipated Actual Learners (n=259)
Participants Participants MD Dematologist
N=3, 1% N=16,
N=1,650 N=913 MD GP / Internal
N=21, 8%
N=21, 8% Medicine
Anticipated Learners as per N=23, 9% MD Other
proposal vs Actual Learners
NP
Anticipated Learners Actual Learners N=28, 11%
(OSP) (OSP) PA
N=750 N=259 N=23, 9% Nurse
Practice Setting N=124, 48%
Pharmacist
HCPs in HCPs in Other (Dietitan, Case
HCPs in Private Manager)
Academic Community Other Setting
Practice
Setting Setting
12% 12% 53% 23%
(N=32) (N=30) (N=136) (N=61)
Medical Education
BMS Grant ID 67832115 Confidential 7
Gains in knowledge, competence, and confidence
(include absolute % for each gain based on pre/post-test responses and indicate the supporting slide referencing
the respective gain)
• Increased familiarity with emerging TYK2 inhibitors (LO1, 16%, slide
Gain #1 7)
Gain #2 • Significantly improved knowledge of the route of administration for
deucravacitinib (LO2, 41%, slide 13)
Gain #3 • Improved competence with selecting therapy for refractory
moderate-to-severe psoriasis (LO3, 3%, slide 16)
Gain #4 • Significantly improved knowledge with TYK2 inhibitor pharmacology
(LO1, 38%, slide 12)
• Significantly increased knowledge of deucravacitinib clinical trial
Gain #5 data (LO1, 36%, slide 14)
Medical Education
BMS Grant ID 67832115 Confidential 8Learner Remaining Practice Gaps
(include absolute % for each gap based on pre/post-test responses and indicate the supporting slide
referencing the respective gap)
• Despite moderate reported confidence with selecting therapy for patients with
Practice Gap #1
refractory moderate-to-severe psoriasis, most learners continued to incorrectly select
therapy for these patients post-activity. Education should focus on experiential learning
(case-based) to foster skills while simultaneously bolstering confidence. (43% post-
activity competence, slide 16; 25% for highest level of confidence, slide 8)
• As the TYK2 inhibitors continue to be developed, clinicians would benefit from
additional education that differentiates TYK2 inhibitors from conventional JAK
Practice Gap #2 inhibitors through engaging education and strategies that support improved knowledge
gains. (25% for highest level of familiarity, slide 7)
• Future education should model evidence based on applying the latest safety data with
the TYK2 inhibitors. Additional education with strategies such as practice aids (eg,
Practice Gap #3
patient workup sheets) and roundtable discussions will provide multidisciplinary team-
based avenues for translating knowledge to practice. (75% post-activity knowledge,
slide 15)
Medical Education
BMS Grant ID 67832115 Confidential 9Clinical
ClinicalFamiliarity:
Familiarity:Emerging
EmergingTYK2
TYK2Inhibitors
Inhibitors
Moore’s Level Achieved: 3
Moore’s Level Achieved: 3
Learning Objective: Evaluate emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy and routes of
Learning Objective: Evaluate emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy and routes
administration
of administration
Question: How familiar are you with emerging TYK2 inhibitors for the treatment of moderate-to-severe psoriasis?
Question: How familiar are you with emerging TYK2 inhibitors for the treatment of moderate-to-severe psoriasis?
Pre, N=256 Post, N=216
9% It is key that clinicians are
Very familiar
25% familiar with the promising TYK2
inhibitors in development for
moderate-to-severe psoriasis.
After completing this activity, the
29% percentage of learners who
Somewhat familiar identified as “very familiar” with
45%
emerging TYK2 inhibitors
increased 16%. This increased
familiarity should translate to
62% more optimized use of these
Not at all familiar agents once they become
30% available.
0% 20% 40% 60% 80% 100%
Medical Education Grant ID: 67832115 Confidential 7Clinical
ClinicalConfidence:
Familiarity:Selecting
EmergingTherapy for Refractory Moderate-to-Severe Psoriasis
TYK2 Inhibitors
Moore’s Level Achieved:
Moore’s Level Achieved: 33
Learning Objective: Model current and future treatment strategies for refractory patients considerate of disease activity, treatment
Learning Objective: Evaluate emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy and routes
response, and other patient-specific factors
of administration
Question: How confident are you with selecting therapy for patients with refractory moderate-to-severe psoriasis?
Question: How familiar are you with emerging TYK2 inhibitors for the treatment of moderate-to-severe psoriasis?
Pre, N=259 Post, N=216
11%
Very confident Clinicians should not only be
25%
competent, but also confident,
with determining optimal therapy
for their patients with refractory
moderate-to-severe psoriasis.
31% Learners who identified as “very
Somewhat confident
49% confident” with this topic
increased 14%. These gains
should translate to more
effective care of patients with
refractory moderate-to-severe
58% psoriasis.
Not at all confident
26%
0% 20% 40% 60% 80% 100%
Medical Education Grant ID: 67832115 Confidential 8Cohen’s d Effect
Clinical Familiarity: Size
Emerging TYK2 = 0.44 (first attempt posttest)
Inhibitors
Moore’s
This EffectLevel Achieved: 3uses pre and posttest question responses from all pre and posttest takers. First attempt posttest scores were
Size calculation
Learning
used Objective:
to calculate Evaluatemean
the posttest emerging TYK2 inhibitors
and standard based on their mechanistic profiles, safety, efficacy and routes
deviation.
of administration
Question: How familiar are you with emerging TYK2 inhibitors for the treatment of moderate-to-severe psoriasis?
Pretest
Mean 42%
Standard
Deviation 0.25
Sample Size 259
Posttest
Mean 54%
Standard
Deviation 0.29
Sample Size 216
An effect size of 0.44 indicates that participating clinicians are approximately 30% more
knowledgeable of the content assessed than prior to participating in this education.
Cohen (1988): .2 = small, .5 = medium, .8 = large
Wolf (1986): .25 = educationally significant, .50 = clinically significant
Cohen’s d effect size accounts for variances in learner populations and is more sensitive to the size of the learner population.
As such, ACHL considers effect size to be a more robust measure of educational effectiveness than normalized gains.
Medical Education Grant ID: 67832115 Confidential 9Cohen’s d Effect
Clinical Familiarity: Size
Emerging TYK2 = 1.31 (last attempt posttest)
Inhibitors
Moore’s
This EffectLevel Achieved: 3uses pre and posttest question responses from all pre and posttest takers. First attempt posttest scores were
Size calculation
Learning
used Objective:
to calculate Evaluatemean
the posttest emerging TYK2 inhibitors
and standard based on their mechanistic profiles, safety, efficacy and routes
deviation.
of administration
Question: How familiar are you with emerging TYK2 inhibitors for the treatment of moderate-to-severe psoriasis?
Pretest
Mean 42%
Standard
Deviation 0.25
Sample Size 259
Posttest
Mean 71%
Standard
Deviation 0.19
Sample Size 216
An effect size of 1.31 indicates that participating clinicians are approximately 66% more
knowledgeable of the content assessed than prior to participating in this education.
Cohen (1988): .2 = small, .5 = medium, .8 = large
Wolf (1986): .25 = educationally significant, .50 = clinically significant
Cohen’s d effect size accounts for variances in learner populations and is more sensitive to the size of the learner population.
As such, ACHL considers effect size to be a more robust measure of educational effectiveness than normalized gains.
Medical Education Grant ID: 67832115 Confidential 10Pretest vs.
Clinical Familiarity: Posttest
Emerging
Moore’s Level Achieved: 3
Summary
TYK2 Inhibitors
51%
Normalized
Learning Objective: Evaluate emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy and routes
of administration Change
Topic
Question: How familiarAbsolute
are you%withAbsolute
emerging% TYK2 inhibitors for the treatment of moderate-to-severe psoriasis? (pre to last
Change Change 100% post)
(pre to 1st (pre to last
post) post) 90% 87%
80% 77% 75%
74%
TYK2 Inhibitor 70%
15% 38% 64%
Pharmacology
60% 56% 56%
49% 50%
Route of Administration 50% 45%
17% 41% 43%
for Deucravacitinib 41% 40% 42%
40%
33%
Deucravacitinib Clinical 30%
15% 36%
Trial Data
20%
Safety Data with 10%
11% 30%
Deucravacitinib
0%
MOA of the TYK2 Route of Efficacy of Safety of Therapy Selection
Therapy Selection for Inhibitor Administration for Deucravacitinib Deucravacitinib for Moderate
2% 3%
Moderate Psoriasis Deucravacitinib Psoriasis
Pre (N=216) 1st Post (n=216) Last Post (N=259)
Medical Education Grant ID: 67832115 Confidential 11Knowledge Acquisition:
Clinical Familiarity: TYK2 Inhibitor
Emerging Pharmacology
TYK2 Inhibitors
Moore’s Level Achieved:
Moore’s Level Achieved: 33
Learning Objective: Evaluate emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy and routes of
Learning Objective: Evaluate emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy and routes
administration
of administration
Question: Which of the following best describes the mechanism of action of the investigational TYK2 inhibitor?
Question: How familiar are you with emerging TYK2 inhibitors for the treatment of moderate-to-severe psoriasis?
Pre, N=259 First Post, N=216 Last Post, N=216
Considering the bevy of adverse events
and black box warnings with the JAK
It exerts its action by binding to the TYK2 catalytic and 12% inhibitors, it is important for clinicians to
16%
regulatory domains
4% understand how TYK2 inhibitors are
P=Knowledge Acquisition:
Clinical Familiarity: Route ofTYK2
Emerging Administration
Inhibitors for Deucravacitinib
Moore’s Level Achieved:
Moore’s Level Achieved: 33
Learning Objective: Assess clinical implications of emerging evidence for in meeting unmet clinical needs for refractory psoriasis
Learning Objective: Evaluate emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy and routes
patients
of administration
Question: What is the route of administration of deucravacitinib?
Question: How familiar are you with emerging TYK2 inhibitors for the treatment of moderate-to-severe psoriasis?
Pre, N=259 First Post, N=216 Last Post, N=216
It is critical for clinicians to
understand the route of administration
7%
Topical cream 5%
for deucravacitinib considering the
3% P=Knowledge Acquisition:
Clinical Familiarity: Deucravacitinib
Emerging Clinical Trial Data
TYK2 Inhibitors
Moore’s Level Achieved:
Moore’s Level Achieved: 33
Learning Objective: Evaluate emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy and routes of
Learning Objective: Evaluate emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy and routes
administration
of administration
Question: Which of the following is correct regarding the efficacy with deucravacitinib?
Question: How familiar are you with emerging TYK2 inhibitors for the treatment of moderate-to-severe psoriasis?
Pre, N=259 First Post, N=216 Last Post, N=216
Clinicians need to understand the
latest evidence with deucravacitinib
5% to ensure it is properly incorporated
Deucravacitinib did not demonstrate superior PASI 75 and PASI
3%
90 responses at Week 16 compared to placebo P=Clinical Familiarity:
Knowledge Emerging
Acquisition: TYK2with
Safety Data Inhibitors
Deucravacitinib
Moore’sLevel
Moore’s Level Achieved:3 3
Achieved:
Learning Objective:Evaluate
LearningObjective: Evaluateemerging
emergingTYK2
TYK2inhibitors
inhibitorsbased
basedonontheir
theirmechanistic
mechanisticprofiles,
profiles,safety,
safety,efficacy
efficacyand
androutes
routesof administration
Question: Which of the following is correct about recent safety data with deucravacitinib?
of administration
Question: How familiar are you with emerging TYK2 inhibitors for the treatment of moderate-to-severe psoriasis?
Pre, N=259 First Post, N=216 Last Post, N=216
It is important that clinicians
16% comprehend not only the efficacy,
Deucravacinib was associated with opportunistic systemic
10% but also the safety considerations
infections
8% P=Clinical Competence: Therapy Selection for Refractory Moderate-to-Severe Psoriasis
ClinicalLevel
Moore’s Familiarity:
Achieved:Emerging
4 TYK2 Inhibitors
Moore’sObjective:
Learning Model 3current and future psoriasis treatment strategies for refractory patients considerate of
Level Achieved:
Learning
disease Objective:
activity, Evaluate
treatment emerging
response, andTYK2 inhibitors
other based on factors
patient-specific their mechanistic profiles, safety, efficacy and routes
Question: Valerie is a 24-year-old female who has been diagnosed with moderate psoriasis (10% BSA). Of note, she also has psoriasis
of administration
involvement
Question: Howon her palms.
familiar areWhich of the
you with following
emerging TYK2would you prescribe
inhibitors as her primary
for the treatment therapy based on
of moderate-to-severe best available data?
psoriasis?
Pre, N=259 First Post, N=216 Last Post, N=216
This question assessed learners’
20% preference for oral therapy. Either
Ustekinumab 18% ustekinumab or apremilast would
16% P=.50 work for this patient case, but the
increase with the selection of
apremilast showed that learners
20%
are more inclined to select oral
Apremilast 24%
27%
therapy post-activity. A significant
proportion of learners incorrectly
chose therapies not indicated or
23% recommended for moderate
Targeted phototherapy 15% psoriasis post-activity, highlighting
13% the need for continued education.
37%
Topical steroids 43%
44%
0% 20% 40% 60% 80% 100%
Medical Education Grant ID: 67832115 Confidential 16Novel Therapy
Clinical Familiarity: Incorporation
Emerging TYK2 Inhibitors
Moore’s Level Achieved: 3
(inter-activity)
Learning Objective: Evaluate emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy and routes
of administration
Question:
Which How familiar
of the following are would
factors you with emerging
make TYK2
you more inhibitors
likely to for the treatment
Howoflikely
moderate-to-severe psoriasis?
are you to incorporate deucravacitinib into
incorporate a novel therapy into practice? practice once it receives FDA approval?
0% 20% 40% 60% 80%
Polling, N=93
Guideline recommendations 58%
15%
Additional clinical trial efficacy data 43% 45%
Data demonstrating safety 53%
FDA approval 58%
40%
Minimal insurance barriers 48%
More colleagues with experience using
23% Very likely Somewhat likely Not at all likely
the agent Polling, N=113
Multiple responses allowed
Over half of learners indicated that they would be more likely to incorporate a novel therapy (such as investigational deucravacitinib)
into practice based on guideline recommendations, data demonstrating safety, and FDA approval. Almost all learners indicated that
they also would be very or somewhat likely to incorporate deucravacitinib into practice once it is approved.
Medical Education Grant ID: 67832115 Confidential 17Novel Therapy
Clinical Familiarity: Incorporation
Emerging TYK2 Inhibitors Cont.
Moore’s Level Achieved: 3
(inter-activity)
Learning Objective: Evaluate emerging TYK2 inhibitors based on their mechanistic profiles, safety, efficacy and routes
of administration
Question:
Which How familiar
of the following are you
concerns dowith
youremerging TYK2with
patients have inhibitors for the treatment of moderate-to-severe
Please estimate the percent psoriasis?
of your patients who
conventional psoriasis therapy? might prefer a safe, effective oral therapy over
injectable therapy for moderate-to-severe psoriasis:
0% 20% 40% 60% 80%
Adverse events/safety concerns 57%
Polling, N=63
2%
4%
Fear of injections/needles 38% 17%
49%
Limitations with efficacy 33%
Insurance barriers 55%
28%
Cost 50%
Polling, N=64
Multiple responses allowed None 1-25% 26-50% 51-75% 76-100%
Learners identified several barriers that continue to persist in refractory moderate-to-severe psoriasis care. Deucravacitinib may be
able to overcome these barriers if the agent has tolerable safety, limited insurance barriers, and cost. Learners also stated that most
of their patients with this condition would prefer a safe, effective oral option over injectable therapy, highlighting potential
opportunities with deucravacitinib.
Medical Education Grant ID: 67832115 Confidential 18Learners’ Planned Change to Practice 12
Post, N=193
Enroll my patients with refractory psoriasis into clinical trials 22%
68% of learners will change their
practice following participation in
Consider comorbidities with psoriasis treatment selection 33% this activity. Among other changes,
33% will consider comorbidities
Ensure comprehensive care of patients with psoriasis (e.g.
30%
with psoriasis treatment selection
optimal management of concomitant conditions) and 31% will consider selecting a
different therapy for moderate-to-
Consider selecting a different therapy for my patients with
moderate-to-severe psoriasis
31% severe psoriasis.
Prescribe new therapies for moderate-to-severe psoriasis as they
22%
become available
This activity validated my current practice; no changes will be
4%
made
Not applicable 28%
0% 10% 20% 30% 40% 50% 60%
Multiple responses allowed
Medical Education INSERT
BMS BMSIDGRANT
Grant ID HERE
67832115 Confidential 19Patient Care Impact 12
Number of patients with moderate-to-severe psoriasis seen per month:
Post, N=193 Changes made from this activity have the
6% potential to impact 555 to more than 970
8% 35% patients with moderate-to-severe psoriasis each
month. This assumes data in the pie chart is
representative of the 259 learners to-date, who
16% indicated they would change their practice as a
result of participating in this activity (68%).
35%
0 1-5 6-10 11-15 >15
Medical Education INSERT
BMS BMSIDGRANT
Grant ID HERE
67832115 Confidential 20Barriers to Change 12
Post, N=193
30% of learners indicated there
Lack of staff time to implement change 15% were no barriers to applying the
changes in their practice. Of those
Do not have an implementation plan 9% HCPs who reported barriers, 72%
will attempt to address the
Insurance/reimbursement issues 32% perceived barrier(s) in order to
affect change.
Cost 27%
Organizational/institutional culture 6%
Patient adherence/compliance 16%
Lack of supporting evidence in the literature 2%
Lack of consensus or professional guidelines 4%
No barriers 30%
Other barriers 5%
0% 10% 20% 30% 40% 50%
Multiple responses allowed
Medical Education INSERT
BMS BMSIDGRANT
Grant ID HERE
67832115 Confidential 21Clinically Valuable Feedback from Learners:
Please list one pearl you took away as a result of participating in this activity:
• A new oral medication may be coming
• Consider comorbidities with psoriasis treatment selection
• Differentiating TYK2 inhibitors from JAK inhibitors
• Multiple uses of TYK2
• Novel agent efficacy and safety, treat scalp as special area
• Oral tx available
• Promising new treatment
• Refer to specialist
• Safe and effective
• Safety reassurance
• Side effects of this medication
• Side effects of treatment
• That the new TYK 2 inhibitor is not immunosuppressive
• That TYK2 inhibitors could help patients have better control of their psoriasis
• The promising nature of deucravacitinib for the treatment of mod- to severe psoriasis
• There is an oral alternative on the horizon for psoriasis and psoriatic arthritis
• This medication has lower incidence of cardiac events compared to Apremilast
• Treatment regimen of patients with psoriatic arthritis Learners have the option to list any
• TYK2 inhibitors are on the horizon for the treatment of moderate to severe plaque psoriasis remaining questions following their
• TYK2 inhibitors are superior to apremilast participation in the activity,
• Understanding pathophysiology of psoriasis however no questions have been
• Value of tyk2 meds received to date.
.
Medical Education
BMS Grant ID 67832115 Confidential 22Clinically Valuable Feedback from Learners:
Learner Satisfaction
Please list one pearl you took away as a result of participating in this activity: 27
N=193
94% 95% 97%
Overall quality of education Overall effective format Faculty were knowledgeable
72% 100% 96%
Learning objectives were met Overall free from commercial bias
Overall relevant content
Medical Education Grant ID: 67832115 ConfidentialEducational Impact Summary
1. Post-intervention, 75% of HCPs stated they are somewhat or very confident in their ability to select
therapy for patients with refractory moderate-to-severe psoriasis, with a positive shift in confidence
of 32 percentage points post intervention.
2. Knowledge and competency improvements were demonstrated across all learning objectives resulting
in an average increase of 29 percentage points from baseline to last attempt posttest. (51%
normalized gain)
3. After participating in this activity, learners identified several barriers that continue to persist in
refractory moderate-to-severe psoriasis care, highlighting potential opportunities with
deucravacitinib.
4. More than three-fourths of learners post-activity highlighted that the majority of their patients would
prefer a safe, effective oral option over injectable therapy.
5. 68% of learners intend to change their practice as a result of this education. Of those, 30% indicated
there were no barriers to applying the changes they indicated on the previous question.
6. Changes made from this activity have the potential to impact 555 to more than 970 patients with
moderate-to-severe psoriasis each month.
Medical Education
BMS Grant ID 67832115 Confidential 24You can also read
